Skip to content

US · PCRX · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Pacira BioSciences, Inc. (PCRX) intrinsic value and stock valuation

$36.48as of 2026-11-21 · Mkt cap 978.26M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pacira BioSciences, Inc. DCF and intrinsic value

InvestorsCraft values PCRX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PCRX’s statements →

Pacira BioSciences, Inc. Graham Number

Graham Number: $7.43d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Brisbane, CA 94005 pacira.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$726.4M+11.1% 5y CAGRd
20112025
Net income
$7.03M-45.4% 5y CAGRd
20112025
Free cash flow
$136.7M+28.4% 5y CAGRd
20112025
Total equity
$693.1M+2.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$726.4M$701M$675M$666.8M$541.5M
Operating income$33.3M-$-73.37M$87.7M$60M$89.9M
Net income$7.03M-$-99.56M$42M$15.9M$42M
EPSd$156.1K-$-2.15M$807K$341.9K$920K
Operating cash flow$152M$189.4M$154.7M$145.3M$125.7M
Capital expenditure-$-15.33M-$-10.64M-$-15.16M-$-30.08M-$-45.87M
Free cash flow$136.7M$178.8M$139.5M$115.2M$79.9M
Total assets$1.26B$1.55B$1.57B$1.68B$2.08B
Total debt$454.4M$638.9M$586M$763.4M$1.13B
Net debt$295.8M$362.1M$432.8M$659.3M$543.3M
Total equity$693.1M$778.4M$870.1M$775M$730.4M
Cash and short-term investments$238.4M$484.6M$278.6M$288.7M$656.4M
Income statement
20252024202320222021
Revenue$726.4M$701M$675M$666.8M$541.5M
Cost of revenue$149.8M$170.4M$184.7M$199.3M$140.3M
Gross profit$576.7M$530.5M$490.3M$467.5M$401.3M
Research and development expenses$117.3M$81.6M$76.3M$84.8M$55.6M
Selling, general and administrative expenses$368.8M$294.1M$269.4M$254.5M$199.3M
Other expenses$57.3M$228.2M$56.9M$68.2M$56.5M
Operating expenses$543.4M$603.9M$402.6M$407.5M$311.4M
Cost and expenses$693.1M$774.3M$587.3M$606.8M$451.6M
Interest income$22.7M$19.7M$11.4M$4.54M$900K
Interest expense$14.6M$16.6M$17.3M$35.6M$29M
Depreciation and amortization$91M$78.8M$75.6M$91.5M$28.6M
Ebitda$122.5M$29.1M$154.6M$140.4M$114M
Operating income$33.3M-$-73.37M$87.7M$60M$89.9M
Total other income/expenses, net-$-16.43M$10.3M-$-25.97M-$-46.72M-$-33.52M
Income before tax$16.9M-$-63.11M$61.7M$13.3M$56.4M
Income tax expense$9.84M$36.5M$19.8M-$-2.61M$14.4M
Net income$7.03M-$-99.56M$42M$15.9M$42M
Weighted average shares outstanding$44.6M$46.2M$46.2M$45.5M$44.3M
Weighted average diluted shares outstanding$45M$46.2M$52M$46.5M$45.6M
Balance sheet
20252024202320222021
Cash and short-term investments$238.4M$484.6M$278.6M$288.7M$656.4M
Net receivables$124.1M$113.3M$105.6M$98.4M$96.3M
Inventory$152.9M$125.3M$104.4M$96.1M$98.6M
Total current assets$548M$745.1M$510M$498.3M$866.1M
Property, plant and equipment, net$182.5M$216.4M$235M$254.4M$264.8M
Goodwill and intangible assets$388.3M$426M$646.5M$703.8M$769.1M
Long-term investments$0.00$29.5M$2.41M$37.2M$0.00
Total non-current assets$716.9M$808.4M$1.06B$1.18B$1.21B
Total assets$1.26B$1.55B$1.57B$1.68B$2.08B
Accounts payable$15.2M$19.1M$15.7M$15.2M$10.5M
Short-term debt$9.84M$210.7M$17.4M$42.8M$382.6M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$120.6M$309.9M$97.4M$147.8M$521.1M
Long-term debt$444.5M$428.2M$568.6M$720.6M$746.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$10.1M
Total non-current liabilities$451.2M$465.3M$606.9M$758.4M$823.8M
Capital lease obligations$36.2M$53.5M$63.6M$73.9M$79.6M
Total liabilities$571.8M$775.2M$704.3M$906.2M$1.34B
Common stock$50K$50K$50K$50K$40K
Retained earnings-$-199.32M-$-206.36M-$-106.8M-$-148.75M-$-211.9M
Accumulated other comprehensive income (loss)$4.33M$340K$250K-$-380K$170K
Total equity$693.1M$778.4M$870.1M$775M$730.4M
Total investments$79.9M$237.3M$127.7M$221.7M$70.8M
Total debt$454.4M$638.9M$586M$763.4M$1.13B
Net debt$295.8M$362.1M$432.8M$659.3M$543.3M
Cash flow statement
20252024202320222021
Net income$7.03M-$-99.56M$42M$15.9M$42M
Depreciation and amortization$91M$78.8M$75.6M$91.5M$28.6M
Stock-based compensation$57.5M$51.2M$47.9M$48.1M$42.3M
Change in working capital-$-38.27M-$-18.52M-$-45.78M-$-16.43M-$-18.67M
Accounts receivable-$-10.74M-$-7.75M-$-7.16M-$-2.08M-$-10.43M
Inventory-$-27.57M-$-20.93M-$-8.29M$2.49M-$-4.47M
Accounts payable-$-5.6M$3.08M$920K$6.27M-$-10.26M
Net cash provided by operating activities$152M$189.4M$154.7M$145.3M$125.7M
Investments in property, plant and equipment-$-15.33M-$-10.64M-$-15.16M-$-30.08M-$-45.87M
Acquisitions, net-$-16.7M$0.00$0.00$0.00-$-420.04M
Net cash used for investing activities$99.5M-$-83.28M$77.5M-$-225.19M-$-20.79M
Common stock issued$3.3M$0.00$0.00$27.3M$26.7M
Common stock repurchased-$-148.33M-$-25M-$-110K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-369.63M$17.4M-$-183.03M-$-401.53M$380.7M
Net change in cash-$-118.23M$123.5M$49.2M-$-481.44M$485.6M
Cash at end of period$158.5M$276.8M$153.3M$104.1M$585.6M
Operating cash flow$152M$189.4M$154.7M$145.3M$125.7M
Capital expenditure-$-15.33M-$-10.64M-$-15.16M-$-30.08M-$-45.87M
Free cash flow$136.7M$178.8M$139.5M$115.2M$79.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pacira BioSciences, Inc.

        Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

        CEO
        Frank D. Lee
        Employees
        829
        Beta
        0.27

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Pacira BioSciences, Inc. (PCRX)?

        Pacira BioSciences, Inc. (PCRX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PCRX undervalued?

        PCRX trades at a price of $36.48 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.